Yeah-Sil Moon is a leading U.S. and Korean patent lawyer as recognized by Chambers, Super Lawyers, and The New York Times. Her 30-year practice is an extraordinarily rich experience of successfully handling patent prosecution, litigation, and strategic counseling matters for clients in the pharmaceutical, biotechnology, chemical, automobile, telecommunication, electronic, mechanical, and medical device sectors. Yeah-Sil has prosecuted and enforced patents worldwide for some of the most successful therapeutics. She has assisted BMS (formerly Celgene Corp.) in establishing its global patent portfolio, including prosecution, strategic counseling, litigation, inter partes review (IPR), opposition, invalidation, and transactions for products including billions dollar a year drugs REVLIMID®, POMALYST®, OTEZLA®, ONUREG®, VIDAZA®, THALOMID®, and ABRAXANE® for treating cancers and immune, inflammatory conditions.
Yeah-Sil has successfully defended patent infringement actions in various district courts and the International Trade Commission (ITC). Recently she achieved a tremendously important victory for SK Innovation against LG Chem in a patent infringement dispute before the ITC involving lithium-ion battery technology used in electric vehicles. She also obtained Federal Circuit's decision affirming a summary judgment of noninfringement for PI Advanced Materials (SKC Kolon PI) and won a jury verdict of noninfringement for SOLiD in the Northern District of California. Yeah-Sil also has in-depth experience in IPR. She has significant experience with patent prosecution, litigation, opposition, and invalidation proceedings in Asia, Europe, Australia, Mexico, and Brazil.
Yeah-Sil leads the Firm's Korea Practice and is a member of the Firm's Patent Prosecution Council. She regularly travels to Korea to visit clients and to lecture on hot topics of U.S. and international IP protection.
Experience
Additional Speaking Engagements
- April 2018
IP Infringement Claims at the U. S. International Trade Commission – A Comparison to U.S. District Court Actions - January 2018
U. S. Patent Litigation and Inter Partes Review Proceedings - December 2017
Intellectual Property Protection Of Artificial Intelligence and Big Data Technologies - September 2017
Drafting U.S. Provisional and Non-Provisional Applications; U.S. Patent Litigation, Discovery, Privilege Protection and Inter Partes Review - May 2017
Issues And Strategic Considerations For The Protection and Use Of Artificial Intelligence Technologies - September 2016
U.S. IPR and Patent Prosecution Strategy - September 2016
Global IP Procurement and Enforcement for Pharmaceutical and Biotechnology Inventions - June 2016
Artificial Intelligence Intellectual Property: Players, Issues, and Strategic Considerations - January 2016
IP Enforcement, Discovery & Privilege Issues in the US - March 2015
Television Interview: Jones Day's Global Presence, TV Korea Daily Pharm - September 26, 2014
IP Enforcement in the US: the Jury Trial, Asia Intellectual Property Finance and Business Conference - September 22, 2014
Inter Partes Review in the United States Patent Office; Deposition and Trial Strategies for Witnesses in United States Lawsuits - April 2014
Growing Pharmaceutical & Health Care Business Using Global Patent Strategy - April 2014
U.S. Patent Litigation Guide and Overview of Standard-Essential Patents - November 2013
Post-Grant Proceedings and New Developments in the U.S. - a Year After the 2011 Patent Law (AIA) - September 10-13, 2013
Recent Developments and Uncertainties in the Law on Patent Eligible Subject Matter; Recent Developments in the ITC and Injunctive Relief For Standard-Essential Patents; US Patent Litigation Reform – Legislative Efforts and Practical Strategy Dealing with Non-Practicing Entities - September 24-28, 2012
US Patent Litigation in the Wake of AIA, and Using the New Post-Grant Proceedings; Strategic Decisions Regarding the Upcoming US Move to a First-To-File System; Myriad Case: Patentable Subject Matter - October 4-7, 2011
The 2011 Patent Reform Act - June 15, 2010
Pharmaceutical Polymorphism and U.S. Patent Law: Recent Developments - March 2009
Comparison and Strategy of U.S. ITC Investigation and Patent Infringement Litigation in U.S. District Courts - September 2008
Patent Procurement and Portfolio Management Strategy - June 1, 2007
Intellectual Property Litigation and ITC Litigation in the U.S.A., Korea Drug Research Association - May 30, 2007
Intellectual Property Litigation and ITC Litigation in the U.S.A., Korea Small Business Corporation Association and Korea Intellectual Property Lawyer Association - August 15, 2004
Patent Litigation and U.S. ITC Litigation, LG Cable Co., Ltd. - August 14, 2004
Effective Patent Portfolio, LG Cable Co., Ltd. - March 25, 2004
Developments in the U.S. Doctrine of Equivalents; IP Due Diligence, Korea Drug Research Association - May 15, 2003
Focus on U.S. Patent Litigation; Patent and Telecommunication Standardization, Korea Telecommunication Technology Association - May 27, 2002
Copyright and Internet, SK Telecom Co., Ltd. - May 26, 2002
Doctrine of Equivalents in the U.S.A., Korean IP Firms - May 25, 2002
Patent Procurement and Litigation in the U.S.A., Hyundai Motor Company and Kia Motor Company
- Yeshiva University, Benjamin N. Cardozo School of Law (J.D. 2002); St. John's University (M.S. in Pharmaceutical Science 1986); Seoul National University, Graduate School of Public Health (1983); Ewha Womans University, Korea (B.S. in Pharmacy 1982)
- New York, Korean Intellectual Property Office, United States Patent and Trademark Office, U.S. Court of Appeals for the Federal Circuit, and U.S. District Court for the Eastern District of New York
Recognized in The New York Times Magazine's "Top Women Attorneys in New York Rising Stars"
Ranked in Chambers Global as a leader in intellectual property for USA and South Korea
Recognized in Super Lawyers as a "Rising Star" in intellectual property
New York Metro Super Lawyers
- Korean, Japanese